HMW-HA Lung Administration for Cytokine Storm Mitigation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for COVID-19 are ineffective in reducing the severity of symptoms and preventing organ damage due to an exacerbated immune response, particularly in individuals with underlying health conditions, leading to a high mortality rate and the need for ventilators.

Innovation Solution

Administering high-molecular weight hyaluronic acid (HMW-HA) to the lungs before the onset of acute respiratory distress syndrome or cytokine storm, along with NAD+ or its precursors and SIRT-pathway stimulants, to dampen the immune response and reduce the severity of COVID-19 symptoms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional supportive treatment is provided to maintain respiration and prevent organ damage, then patient survival is attempted, but mortality rate remains significant particularly in elderly and immune compromised individuals

Engineering Contradiction:

Improvepatient survival rateVSAvoidmortality rate

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent administers high-molecular weight hyaluronic acid (HMW-HA) at the time of COVID-19 diagnosis, before the immune system escalates to produce damaging cytokines. This preliminary intervention prevents the formation of harmful inflammatory responses before they can cause organ damage, rather than attempting to treat after damage has occurred.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

HMW-HA acts as an intermediary substance that modulates the immune response by preventing excessive cytokine production. It mediates between the viral infection and the immune system, dampening the harmful inflammatory response while allowing the immune system to continue fighting the virus effectively.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If the immune response is allowed to escalate to fight the virus, then viral clearance is achieved, but tissue and organ damage occurs due to cytokine storm

Engineering Contradiction:

Improveviral clearance effectivenessVSAvoidtissue and organ damage

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies HMW-HA specifically to the respiratory tract where the viral infection occurs. This localized treatment modulates the immune response precisely where needed - in the lungs and respiratory tissues - allowing systemic immune functions to remain intact while preventing local tissue damage from cytokine storm.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent changes the parameter of immune response intensity by introducing HMW-HA, which shifts the immune response from an excessive, damaging state to a controlled, effective state. This parameter change allows the immune system to maintain viral clearance capability while reducing harmful inflammation to acceptable levels.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS11780871B1COVID-19 treatment and methods

Publication Date: 2023.10.10 EMBRIENT INC

AI summary

Compositions and methods are presented that reduce the risk for ARDS and/or need for ventilation in a patient diagnosed with a coronavirus, and particularly SARS-CoV-2 virus, a SARS virus, or a MERS virus. In preferred aspects, HMW-HA is administered to the lung before onset of ARDS and/or cytokine storm. Additionally, NAD+ may be co-administered or prophylactically administered where NAD+levels are low.